GlassScriptPhysician profile
Tara Howard
NPI 1316688260
$6,112.44
in general payments reported to CMS, 2019-2025
23 companies · $2,359 in 2025
The $2,359 reported for 2025 was more than what 97% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $981 · 2024: $2,772 · 2025: $2,359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,865 · Education: $247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,865.46 |
| Education | $246.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,675.02 | 2023-2025 | |
| Genzyme Corporation | $644.15 | 2023-2025 | |
| Ucb, INC. | $626.84 | 2023-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $609.45 | 2024-2025 | Tremfya |
| Arcutis Biotherapeutics, INC. | $450.53 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $288.37 | 2024-2025 | Anzupgo, Adbry |
| Novartis Pharmaceuticals Corporation | $243.89 | 2023-2025 | |
| Amgen INC. | $241.47 | 2024-2025 | Otezla, Otezla |
| Incyte Corporation | $230.59 | 2023-2025 | Opzelura |
| Lilly USA, LLC | $185.17 | 2023-2025 | Taltz, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $183.62 | 2023-2024 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $158.48 | 2024 | Sotyktu |
| Galderma Laboratories, L.P. | $103.27 | 2023-2025 | Nemluvio |
| Dermavant Sciences, INC. | $102.19 | 2024 | Vtama |
| Sanofi-Aventis U.S. LLC | $79.99 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lnhc, INC | $76.14 | 2025 | Zelsuvmi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.83 | 2024-2025 | Spevigo |
| Organogenesis INC. | $41.07 | 2025 | Puraply Wound Matrix |
| Convatec INC. | $36.36 | 2024 | |
| Blueprint Medicines Corporation | $24.06 | 2025 | Ayvakit |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $20.07 | 2024 | Siliq |
| Biofrontera INC. | $18.35 | 2024 | Rhodoled Xl, Xepi, Bf-Rhodoled |
| Helsinn Therapeutics (U.S.), INC. | $16.53 | 2025 | Valchlor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Howard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.